By: Kairos Ventures On: December 7, 2023 In: Delpor, Portfolio News

Delpor is sketching out late-stage clinical trial plans for its drug-device combination implant DLP-114 (risperidone) in schizophrenia. After presenting topline...

Read more
By: Kairos Ventures On: November 16, 2023 In: Delpor, Portfolio News

Delpor announced topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients received treatment for up...

Read more
By: Kairos Ventures On: April 28, 2022 In: Delpor, Portfolio News

Delpor announced that it has initiated and dosed the first subjects in a phase 1 clinical trial of DLP-160,...

Read more
By: Kairos Ventures On: November 16, 2021 In: Delpor, Portfolio News

Delpor announced an NIH grant award of $2.5 million for the further advancement of the company’s tizanidine implant product...

Read more
By: Kairos Ventures On: April 22, 2021 In: Delpor, Portfolio News

Delpor announced that it has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114,...

Read more
By: Kairos Ventures On: October 14, 2019 In: Delpor, Portfolio News

The National Institutes of Health (NIH) has awarded Delpor, Inc. a grant for the development of a Once-Yearly Naltrexone...

Read more
By: Kairos Ventures On: August 10, 2017 In: Delpor, Portfolio News

Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...

Read more
By: Kairos Ventures On: June 15, 2017 In: Delpor

The NIDDK continues to fund Delpor's efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device...

Read more
By: Kairos Ventures On: May 31, 2017 In: Delpor, Portfolio News

Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing...

Read more
By: Kairos Ventures On: March 7, 2017 In: Delpor, Portfolio News

We are delighted to announce that our portfolio company Delpor has been issued another patent by the United States...

Read more